Colleen Jay, MD
Transplant Surgery · San Antonio, TXNPI 1275700288
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Intuitive Surgical at 43.5% of the total. Reporting peaked in 2019 at $6,325 and has fallen 65.7% since, to $2,167 in 2025.
Across 21 payments — averaging $724.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Veloxis Pharmaceuticals, Inc.$6K
- Transmedics, Inc.$2K
- Sanofi-aventis U.S. LLC$146
- Avanos Medical$94
Across 35 payments — averaging $573.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$20K
What the payments were for
- Consulting fees$6,32542%
- Travel & lodging$4,20328%
- Food & beverage$6824%
- Education$4,00026%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $6,623 |
| Veloxis Pharmaceuticals, Inc. | 1 | $6,325 |
| Transmedics, Inc. | 2 | $2,021 |
| Sanofi-aventis U.S. LLC | 1 | $146 |
| Avanos Medical | 1 | $94 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$6,325
- Da Vinci Surgical System$6,246
- ORGAN CARE SYSTEM$2,021
- THYMOGLOBULIN$146
How this compares
$15,210 in reported general payments places this provider in the 85th percentile of 70 transplant surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Valganciclovir Hcl | 32 | $4,520 |
| Fluconazole | 12 | $315 |
| Tamsulosin Hcl | 14 | $115 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 58 | $110 |
| Omeprazole | 15 | $88 |
| Famotidine | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in San Antonio
- Lokesh BathlaSan Antonio$11K
- Luke ShenSan Antonio$5K
- Elizabeth ThomasSan Antonio$5K
- Eric TreatSan Antonio$2K
- Sidharth SharmaSan Antonio$1K
- Francisco CigarroaSan Antonio$563
- Nassir ThaljiSan Antonio$512
- Preston FosterSan Antonio$491
- Asish MisraSan Antonio$358
- Jonathan CullenSan Antonio$302
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.